Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GBIO logo GBIO
Upturn stock ratingUpturn stock rating
GBIO logo

Generation Bio Co (GBIO)

Upturn stock ratingUpturn stock rating
$6.66
Last Close (24-hour delay)
Profit since last BUY27.83%
upturn advisory
Consider higher Upturn Star rating
BUY since 21 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: GBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $80.5

1 Year Target Price $80.5

Analysts Price Target For last 52 week
$80.5 Target price
52w Low $3
Current$6.66
52w High $29.4

Analysis of Past Performance

Type Stock
Historic Profit -6.81%
Avg. Invested days 24
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 44.86M USD
Price to earnings Ratio -
1Y Target Price 80.5
Price to earnings Ratio -
1Y Target Price 80.5
Volume (30-day avg) 7
Beta 2.67
52 Weeks Range 3.00 - 29.40
Updated Date 08/15/2025
52 Weeks Range 3.00 - 29.40
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -10.84

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date 2025-08-06
When -
Estimate -0.2783
Actual -3.0445

Profitability

Profit Margin -
Operating Margin (TTM) -2928.37%

Management Effectiveness

Return on Assets (TTM) -20.95%
Return on Equity (TTM) -85.45%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -11180277
Price to Sales(TTM) 2.11
Enterprise Value -11180277
Price to Sales(TTM) 2.11
Enterprise Value to Revenue 5.1
Enterprise Value to EBITDA -0.34
Shares Outstanding 6735540
Shares Floating 4936952
Shares Outstanding 6735540
Shares Floating 4936952
Percent Insiders 14.24
Percent Institutions 65.22

ai summary icon Upturn AI SWOT

Generation Bio Co

stock logo

Company Overview

overview logo History and Background

Generation Bio Co. was founded in 2016 and is a biotechnology company focused on developing genetic medicines for liver and other disorders. The company is pioneering a gene therapy platform based on closed-ended DNA (ceDNA), aiming to overcome limitations of existing gene therapies.

business area logo Core Business Areas

  • Genetic Medicine Development: Focuses on developing gene therapies for a range of diseases, including liver, lung, and ophthalmic disorders using its proprietary ceDNA platform.
  • ceDNA Platform Technology: Developing and refining its closed-ended DNA (ceDNA) platform to enable durable, redosable gene therapies.

leadership logo Leadership and Structure

The leadership team includes Philippe Leboulch, MD, as Chief Executive Officer. The organizational structure includes research and development, clinical operations, and business development departments.

Top Products and Market Share

overview logo Key Offerings

  • GBT001 (Phenylketonuria Program): A ceDNA-based gene therapy candidate for phenylketonuria (PKU). The drug is in preclinical stage. Key competitors include BioMarin Pharmaceutical (KUVAN and PALYNZIQ) and Homology Medicines (gene editing approach).
  • Hemophilia A Program: A ceDNA-based gene therapy candidate for hemophilia A. The drug is in preclinical stage. Key competitors include BioMarin (ROCTAVIAN) and CSL Behring (gene therapy programs).

Market Dynamics

industry overview logo Industry Overview

The gene therapy market is rapidly growing, driven by advancements in delivery technologies and increasing regulatory approvals. It is a competitive landscape with many pharma and biotech companies focusing on different targets and technologies.

Positioning

Generation Bio is positioned as an innovator in the gene therapy space, focusing on developing redosable and durable therapies based on its ceDNA technology. This could provide a competitive advantage over viral vector-based therapies.

Total Addressable Market (TAM)

The global gene therapy market is projected to reach USD 25 billion by 2027. Generation Bio is positioned to capture a portion of this TAM through its innovative ceDNA platform.

Upturn SWOT Analysis

Strengths

  • Proprietary ceDNA technology
  • Potential for redosable gene therapies
  • Strong preclinical data
  • Experienced leadership team

Weaknesses

  • Early stage of development
  • High cash burn rate
  • Reliance on a single technology platform
  • Lack of approved products

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Advancements in delivery technologies
  • Regulatory approvals for gene therapies

Threats

  • Competition from established gene therapy companies
  • Clinical trial failures
  • Regulatory hurdles
  • Patent disputes

Competitors and Market Share

competitor logo Key Competitors

  • BMRA
  • SRPT
  • VRTX
  • BLUE

Competitive Landscape

Generation Bio differentiates itself through its ceDNA technology, which aims to address limitations of existing gene therapies. However, it faces strong competition from established players.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by expansion of research and development programs and advancements in ceDNA technology.

Future Projections: Future growth is dependent on successful clinical trials and potential partnerships. Analyst projections vary widely.

Recent Initiatives: Recent initiatives include advancing preclinical programs into clinical trials and exploring new therapeutic areas.

Summary

Generation Bio is a promising early-stage biotech company with innovative ceDNA technology. While the technology holds great potential and preclinical data is encouraging, it is still in the early stages of development and faces significant clinical and regulatory risks. The company needs to successfully navigate clinical trials and secure partnerships to realize its full potential. Significant cash burn and competition remain critical challenges.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • Industry publications

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market share data are estimates and may not be precise. Investing in biotech companies involves significant risks.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Generation Bio Co

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2020-06-12
President, CEO & Director Dr. Cameron Geoffrey McDonough M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 115
Full time employees 115

Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.